TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Tumor Responders in Progressive Breast Cancer or Recurrent Breast Cancer to Exemestane Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Post-operative Adjuvant Therapy Participants With Breast Cancer Recurrence Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients falsely not diagnosed with osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Outcome of Death, Myocardial Infarction, Heart Failure Hospitalization, and Cerebral Vascular Accident
Endpoint domain: Mortality/survival
Primary endpoint: Change in estimated glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in urinary microalbumin/creatinine ratio (uACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of N terminal pro B type natriuretic peptide (NT-prpBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinician-Administered PTSD Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Number of Total Migraine Days Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Colorectal Cancer Screening Uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC from time zero to time of last quantifiable concentration (AUC (0-T))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time zero extrapolated to infinite time (AUC (INF))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of 5% Minoxidil milky lotion compared to 5% Minoxidil solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average total MSAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average total FACT-G score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in arterial partial CO2 pressure (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Clinical Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleth variability index (PVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Completing a Self-sampling Test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Function Capability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion of Follow-up Test
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Neuropeptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self Care Agency Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rational Drug Use Scale
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in body circumferences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in estimated body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Measurable Concentration (AUC[0-t]) of Paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-life (t1/2) of Paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) of Primaquine and Carboxyprimaquine in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of CD3E mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of CXCL10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of 18s rRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Development of GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: The generation and magnitude of an immunological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stone Free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less irritation with anterior-inferior plating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less need for hardware removal
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Emmetropic Subjects Who Are Spectacle Independent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACE Events
Endpoint domain: Mortality/survival
Primary endpoint: MACE Events
Endpoint domain: Adverse events/effects
Primary endpoint: Crestal Bone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate based on RECIST1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Suicide outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Rate of conversion to dementia
Endpoint domain: Mortality/survival
Primary endpoint: Serum concentration of antibiotic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC v3.0 Functional Limitations Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Harris Hip Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Implant Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Not hospitalized
Endpoint domain: Mortality/survival
Primary endpoint: ED utilization rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Infusion related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence of infused T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Replication competent retrovirus
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-free survival (PFS) rate at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Change in fibroid devascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CORRECTS scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of self-reported symptoms of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Minimum Effective Concentration of Ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deep surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects who achieve Hepatitis B e antigen (HBeAg) seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percent of subjects with serious adverse events (SAEs) and discontinuations due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: New Presence of ACP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with controlled BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Net clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in motor threshold for urethral sphincter contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative Risk of C-diff infection
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: muscle strength responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle hypertrophy responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events during combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Bilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Vitamin A stores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total dietary vitamin A intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: HBV viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of shifting to compounded PN due to elevated electrolyte levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of patients vaccinated against influenzae virus
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients vaccinated against streptococcus pneumoniae
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients vaccinated against DTP
Endpoint domain: Adverse events/effects
Primary endpoint: Pulp and Apical regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compensatory Reserve Index (CRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MAO-A specific distribution volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion and rates of children with one or more episodes of malaria or anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of women using a contraceptive method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants with Prophylactic Treatment Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Acute Episode Treatment Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Adverse Experiences (AEs) Related to Protein C Concentrate Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cartilage turnover measured by CTX-II biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in neurodevelopmental deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Time Contacting Objects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Observed maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality assessments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Surgical complications necessitating retreatment
Endpoint domain: Adverse events/effects
Primary endpoint: Physician Global Assessment (PGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-Form 36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of total score in WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 eradication time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lithium sweat concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyotrophic Lateral Sclerosis Specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnosis of IgE-mediated food allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Actigraphic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systematic Observation Scale measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crohn's Disease Activity Index (CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Subject Global Assessment (SGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject Quality of Life (SQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of Physical Activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of progression of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum metal ion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Adverse and Serious Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum levels of the ALT liver enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of the AST liver enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fits Controlled
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cessation of illicit opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in high risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improved HIV therapy adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastmilk microbiota profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracer uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Status of Fracture Union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Depression Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of negative changes on the post-hospitalization behavior questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients Responding to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Plasma Concentration at Steady-state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to 6 Hours at Steady-state (AUC0-6h,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Retention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Dose-limiting toxicity of proposed vorinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility in terms of completing 3 courses of induction therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prognostic value of histopathological classification of pediatric medulloblastoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Coefficient of Variation of Endothelial Cell Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Hexagonality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Assessment of Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifting and tightening of skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of responders at each dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of clinical responders at each dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between clot firmness time, clotting time, and INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Outcome Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADHD Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response - Plasma cytokine profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response - Phenotype of circulating cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and proportion of subjects reporting solicited local reactions and severity of the local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of subjects reporting solicited systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of subjects with abnormal haematology, blood chemistry lab assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: insulin-mediated glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma GSK2248761 Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(0-infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK2248761 Area under the concentration-time curve over the dosing interval (AUC (0 - t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GSK2248761 Maximum observed concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diagnostic accuracy for skin cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number needed to screen (NNS) to identify 1 skin tumor
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient-rated well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pre dialysis potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intradialytic potassium gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: dcSAM content of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: N1-monoacetylspermidine content of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Responders at Month 3 Based on Daily Assessment of Non-Menstrual Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pain-Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reader diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dermatomyositis-associated Calcinosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 minute walk test level of assistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IgG levels against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IPSS (International Prostate Symptom Score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Qmax (Maximum Urinary Flow Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: First analgesic request
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients with acute rejection detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mayo-Portland Adaptability Inventory-4 (MPAI-4) at end of rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Mayo-Portland Adaptability Inventory-4 (MPAI-4) at 1-year post-rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life after Brain Injury (QOLIBRI) status at 1-year post-rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stool sample C. diff toxin assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Arteriovenous fistula caliber
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes